By Marie Rosenthal
Switching from a standard regimen of antiretroviral therapy to bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead Sciences) can be effective in Black Americans with HIV who are virologically suppressed, including those with preexisting resistance, according to a presentation at IDWeek 2020 (poster 1048).
Researchers reported 48-week results from the BRAAVE 2020 trial, a phase 3 clinical trial evaluating treatment responses of virologically suppressed